Indian pharmaceutical company Zydus Cadila announced on Thursday that it has applied for the emergency use approval for its Covid-19 vaccine, ZyCoV-D. So far, the world has seen vaccines based on mRNA technology, such as Pfizer and Moderna, or ones based on viral vectors like Covishield. Zydus conducted late-stage trials in more than 28,000 volunteers nationwide, with nearly 1,000 volunteers belonging to the age group of 12 to 18. The manufacturer has applied for approval of its three-dose vaccine but a two-dose regimen is also currently being evaluated. The three doses are to be administered intradermally at day 0, day 28, and finally on day 56.

Source: Hindustan Times July 01, 2021 09:11 UTC